Explore the latest in heart failure with preserved ejection fraction, including its pathophysiology, treatment, and long-term outcomes.
This randomized clinical trial compares the effect of 4 weeks’ administration of inhaled, nebulized inorganic nitrite vs placebo on exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).
This case-control study investigates whether if the normalized reciprocal of the plasma level of cardiac bridging integrator 1 protein differs in patients with heart failure with preserved ejection fraction, patients with risk factors for heart failure, and individuals with neither heart failure nor risk factors.
This randomized clinical trial evaluates the 1-year safety, patency, and clinical outcomes of a transcatheter interatrial shunt device for patients with heart failure, compared with patients treated with a sham control procedure.
This secondary analysis of the TOPCAT randomized clinical trial examines the association of age, race/ethnicity, obesity, renal function, and atrial fibrillation with levels of natriuretic peptides in heart failure with preserved ejection fraction in people in the Americas.
This secondary analysis of the Women’s Health Initiative cohort discerns whether high-risk APOL1 genotypes are associated with cardiovascular disease and stroke in postmenopausal African American women at high risk for these conditions.
This observational study examines the mortality of patients with systolic blood pressure and other outcomes in heart failure with preserved ejection fraction.
This cohort study identifies the hemodynamic characteristics and outcomes of pulmonary hypertension associated with heart failure with preserved ejection fraction.
This cohort study investigates whether myocardial fibrosis is similarly prevalent in both those with heart failure with preserved ejection fraction (HFpEF) and those at risk for HFpEF, similarly associating with disease severity and outcomes.
This study uses samples from the RELAX clinical trial to determine the effect of sildenafil treatment among individuals with heart failure with preserved ejection fraction.
This study evaluates the clinical predictors of troponin elevation and its association with in-hospital and long-term outcomes among patients with decompensated heart failure with preserved ejection fraction.
This study describes the diagnostic accuracy of technetium 99m pyrophosphate cardiac imaging for detecting transthyretin cardiac amyloidosis in patient with suspected disease.
This cohort study uses Swedish national registry data to compare mortality after coronary artery bypass grafting in patients with preoperative heart failure and reduced vs preserved ejection fraction.
This review examines evidence for the use of mineralocorticoid receptor antagonists in the treatment of heart failure and resistant hypertension.
This Viewpoint discusses management of heart failure with preserved ejection fraction (HFpEF) and lessons learned from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial.
This randomized clinical trial determines whether diet or exercise improves exercise capacity and quality of life among obese older patients with heart failure with preserved ejection fraction (HFPEF).
An anaylis of Swedish registy databases found that β-blockers reduced all-cause mortality but did reduce combined all-cause mortality or heart failure hospitalization among patients with preserved ejection fraction.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: